Biopharma Wins $1 In Del. IP Suit Over Ex-CEO's Wrongdoing

Law360 (June 23, 2021, 7:12 PM EDT) -- A Delaware vice chancellor on Wednesday ruled that, although the former CEO of Macrophage Therapeutics Inc. breached his fiduciary duty to the biopharma company through a "series of conflicted transactions," only $1 in damages will be awarded as no real harm was done.

Vice Chancellor Joseph R. Slights III ruled that Dr. Michael M. Goldberg, who served as CEO of Macrophage until February 2019, breached his fiduciary duty to the company related to transactions that led to a "prized asset" being transferred to an entity he formed.

"Macrophage failed to prove anything more than nominal damages resulting from Dr. Goldberg's fiduciary...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!